相似文献
1
Effect of pioglitazone on energy intake and ghrelin in diabetic patients.
Diabetes Care. 2010 Apr;33(4):742-4. doi: 10.2337/dc09-1600. Epub 2010 Jan 12.
2
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Diabetes Obes Metab. 2009 Apr;11(4):330-7. doi: 10.1111/j.1463-1326.2008.00965.x.
3
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
J Diabetes Complications. 2010 Sep-Oct;24(5):289-96. doi: 10.1016/j.jdiacomp.2009.05.004. Epub 2009 Jul 4.
4
Total and acylated ghrelin levels in type 2 diabetic patients: similar levels observed after treatment with metformin, pioglitazone or diet therapy.
Exp Clin Endocrinol Diabetes. 2009 Sep;117(8):386-90. doi: 10.1055/s-0029-1220936. Epub 2009 Jul 23.
5
Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes.
J Clin Endocrinol Metab. 2012 May;97(5):1615-22. doi: 10.1210/jc.2011-2243. Epub 2012 Mar 14.
6
Oral pioglitazone administration increases food intake through ghrelin-independent pathway in Zucker fatty rat.
Diabetes Res Clin Pract. 2007 Sep;77(3):351-6. doi: 10.1016/j.diabres.2007.01.016. Epub 2007 Feb 23.
7
Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Diabetologia. 2013 Oct;56(10):2153-63. doi: 10.1007/s00125-013-2976-z. Epub 2013 Jun 30.
8
Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study.
Diabetologia. 2012 Apr;55(4):915-25. doi: 10.1007/s00125-011-2447-3. Epub 2012 Jan 12.
9
Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study.
Diabetes Care. 2012 Feb;35(2):252-8. doi: 10.2337/dc11-1107. Epub 2011 Dec 30.
10
Effects of vitamin D combined with pioglitazone hydrochloride on bone mineral density and bone metabolism in Type 2 diabetic nephropathy.
Biosci Rep. 2017 Mar 27;37(2). doi: 10.1042/BSR20160544. Print 2017 Apr 28.
引用本文的文献
1
GIPR Agonism Enhances TZD-Induced Insulin Sensitivity in Obese IR Mice.
Diabetes. 2024 Feb 1;73(2):292-305. doi: 10.2337/db23-0172.
2
Type 2 diabetes subgroups and potential medication strategies in relation to effects on insulin resistance and beta-cell function: A step toward personalised diabetes treatment?
Mol Metab. 2021 Apr;46:101158. doi: 10.1016/j.molmet.2020.101158. Epub 2020 Dec 30.
3
Effects of pioglitazone on insulin sensitivity and serum lipids in obese cats.
J Vet Intern Med. 2014 Jan-Feb;28(1):166-74. doi: 10.1111/jvim.12255.
4
Improved post-prandial ghrelin response by nateglinide or acarbose therapy contributes to glucose stability in Type 2 diabetic patients.
J Endocrinol Invest. 2013 Jul-Aug;36(7):489-96. doi: 10.3275/8811. Epub 2013 Jan 14.
本文引用的文献
1
Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
J Diabetes Complications. 2010 Sep-Oct;24(5):289-96. doi: 10.1016/j.jdiacomp.2009.05.004. Epub 2009 Jul 4.
2
Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Diabetes Obes Metab. 2009 Apr;11(4):330-7. doi: 10.1111/j.1463-1326.2008.00965.x.
3
Pleiotrophic and anti-inflammatory effects of pioglitazone precede the metabolic activity in type 2 diabetic patients with coronary artery disease.
Atherosclerosis. 2008 Mar;197(1):311-7. doi: 10.1016/j.atherosclerosis.2007.05.006. Epub 2007 Jun 22.
4
Consistency of food intake over four eating sessions in the laboratory.
Eat Behav. 2005 Dec;6(4):365-72. doi: 10.1016/j.eatbeh.2005.03.002. Epub 2005 Apr 26.
5
Effect of pioglitazone on body composition and energy expenditure: a randomized controlled trial.
Metabolism. 2005 Jan;54(1):24-32. doi: 10.1016/j.metabol.2004.07.008.
6
Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients.
J Clin Endocrinol Metab. 2002 Jun;87(6):2784-91. doi: 10.1210/jcem.87.6.8567.
7
Development and validation of the food-craving inventory.
Obes Res. 2002 Feb;10(2):107-14. doi: 10.1038/oby.2002.17.
8
Reproducibility, power and validity of visual analogue scales in assessment of appetite sensations in single test meal studies.
Int J Obes Relat Metab Disord. 2000 Jan;24(1):38-48. doi: 10.1038/sj.ijo.0801083.
9
The moderator-mediator variable distinction in social psychological research: conceptual, strategic, and statistical considerations.
J Pers Soc Psychol. 1986 Dec;51(6):1173-82. doi: 10.1037//0022-3514.51.6.1173.
Zotero 插件